Molecular adsorbent recirculating system (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients

International Journal of Artificial Organs

Volumn 29, Issue 2, 2006, Pages 207-218

  Stefoni, Sergio ^a,b   Coli L ^a   Bolondi, L ^a   Donati, G ^a   Ruggeri, G ^a   Feliciangeli, G ^a   Piscaglia, F ^a   Silvagni, E ^a   Sirri, M ^a   Baraldi, O ^a   Soverini, M L ^a   Cianciolo, G ^a   Boni, P ^a   Patrono, D ^a   Ramazzotti, E ^a   Motta, R ^a   Roda, A ^a   Simoni, P ^a   Magliulo, M ^a   Borgnino, L C ^a   Ricci, D ^a   Mezzopane, D ^a   Cappuccilli, M L ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ammonia; Artificial liver; Bilirubin; Blood purification; Encephalopathy; Liver failure; MARS; Renal failure

Indexed keywords

BIOCOMPATIBILITY; BLOOD PRESSURE; DIAGNOSIS; DIALYSIS; HEMODYNAMICS; HEMOGLOBIN; NEURODEGENERATIVE DISEASES; PATIENT REHABILITATION; PLATELETS; PURIFICATION;

ACUTE LIVER FAILURE; ACUTE-ON-CHRONIC LIVER FAILURE; ARTIFICIAL LIVER; BILIRUBIN; BLOOD PURIFICATION; HAEMODYNAMICS; LIVER FAILURE; MOLECULAR ADSORBENT RECIRCULATING SYSTEM; RECIRCULATING SYSTEM; RENAL FAILURE;

AMMONIA;

AMMONIA; BILIRUBIN; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CREATININE; ELECTROLYTE; HEMOGLOBIN;

ADULT; AGED; ALBUMIN DIALYSIS; AMMONIA BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCOMPATIBILITY; BLOOD LEVEL; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ELECTROLYTE BLOOD LEVEL; FEMALE; HEART INDEX; HEART OUTPUT; HEMODYNAMIC MONITORING; HEMOGLOBIN DETERMINATION; HEPATIC ENCEPHALOPATHY; HUMAN; LEUKOCYTE; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; MEAN ARTERIAL PRESSURE; OUTCOMES RESEARCH; PATIENT SATISFACTION; PROGNOSIS; SCORING SYSTEM; STUDENT T TEST; SURVIVAL TIME; THROMBOCYTE;

EID: 33645816327     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880602900207     Document Type: Article

References (43)

1. Sen S, Jalan R, Williams R. Liver failure: Basis of benefit of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 2003; 35: 1306-11.
2. Gill RQ, Sterling RK. Acute liver failure. J Clin Gastroenterol 2001; 33: 191-8.
3. Rahman T, Hodgson H. Clinical management of acute hepatic failure. Intensive Care Med 2001; 27: 467-76.
4. Mitzner SR, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12 (suppl 17): S75-82.
5. Stange J, Ramlow W, Mitzner SR, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-13.
6. Kramer L, Gendo A, Madl C, Ferrara I, Funk G, Schrenk P, Sunder-Plassmann G, Hörl WH. Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis 2000; 36: 1193-200.
7. Stefoni S, Colì L, Feliciangeli G, Scolari MP, Bonomini V. Hemoperfusion in reduced-time programmes for chronic uremia. Long-term results. Int J Artif Organs 1986; 9: 297-300.
8. Kaplan AA, Epstein M. Extracorporeal blood purification in the management of patients with hepatic failure. Semin Nephrol 1997; 17: 576-82.
9. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 24-31.
10. Stange J, Mitzner S, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Löhr M, Liebe S, Shareck W, Hopt UT, Schmidt R. Molecular adsorbent recirculating system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-30.
11. Stange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Hentschel G, Schulz M, Löhr M, Liebe S, Schareck W, Hopt UT. Liver support by extracorporeal blood purification: A clinical observation. Liver Transpl 2000; 6: 603-13.
12. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Pesynski P, Freytag J, Hickstein H, Loock J, Löhr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
13. Stange J, Hassanein TK, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbent recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26: 103-10.
14. Evenepoel P, Maes B, Wilmer A, Nevens F, Fevery J, Kuypers D, Bemmens B, Vanrenterghem Y. Detoxifying capacity and kinetics of the molecular adsorbent recycling system. Blood Purif 2003; 21: 244-52.
15. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: A randomized controlled study. Liver Transpl 2004; 10: 1109-19.
16. Novelli G, Rossi M, Pretagostini R, Poli L, Novelli L, Berloco P, Ferretti G, Iappelli M, Cortesini R. MARS (Molecular adsorbent recirculating system): Experience in 34 cases of acute liver failure. Liver 2002; 22 (suppl 2): 43-7.
17. Bolondi L, Piscaglia F, Camaggi V, Grazi GL, Cavallari A. Review article: Liver transplantation for HCC. Treatment options on the waiting list. Aliment Pharmacol Ther 2003; 17 (suppl 2): S145-50.
18. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468-75.
19. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
20. Botero RC, Lucey MR. Organ allocation: Model for end stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else. Clin Liver Dis 2003; 7: 715-27.
21. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: Final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
22. Roda A, Festi D, Armanino C, Rizzoli R, Simoni P, Minutello A, Roda E. Methodological and clinical aspects of bile acid analysis in biological fluids. In: Progress in clinical biochemistry and medicine, Vol. 8. Berlin, Heidelberg: Springer-Veriag; 1989. p 129-73.
23. Fuller H. The validity of cardiac output measurement by thoracic impedance: A meta analysis. Clin Invest Med 1992; 15: 103-12.
24. Stockmann HB, Ijzermans JN. Prospects for the temporary treatment of acute liver failure. Eur J Gastroenterol Hepatol 2002; 14: 195-203.
25. Klammt S, Stange J, Mitzner SR, Peszynski P, Peters E, Liebe S. Extracorporeal liver support by recirculating albumin dialysis: Analysing the effect of the first clinically used generation of the MARSystem. Liver 2002; 22 (suppl 2): S30-4.
26. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study. Hepatology 2002; 36: 949-58.
27. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: A prospective controlled trial. Liver Transpl 2003; 9: 290-7.
28. Lahdenpera A, Koivusalo AM, Vakkuri A, Hockerstedt K, Isoniemi H. Value of albumin dialysis therapy in severe liver insufficiency. Transpl Int 2005; 17: 717-23.
29. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. Clin Nephrol 2002; 58: 376-83.
30. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Filser D. Prometheus®-a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984-90.
31. Senf R, Klingel R, Kurz S, Tullius S, Sauer I, Frei U, Schindler R. Bilirubin-adsorption in 23 critically ill patients with liver failure. Int J Artif Organs 2004; 27: 717-72.
32. Doria C, Doyle HR, Mandalà L, Marino IR, Caruana G, Gruttadauria S, Lauro A, Magnone M, Scotti Foglieni C, Lamonaca V, Scott VL. Changes in serum electrolytes during treatment of patients in liver failure with molecular adsorbent recirculating system. Int J Artif Organs 2003; 26: 918-23.
33. Stefoni S, Cianciolo G, Donati G, Colì L, La Manna G, Raimondi C, Dalmastri V, Orlandi V, D'Addio F. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron 2002; 92: 589-600.
34. Aggarwal A, Whitaker DA, Rimmer JM, Solomon RJ, Gennari FJ, Sobel BE, Schneider DJ. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. Nephrol Dial Transplant 2004; 19: 1559-63.
35. Stefoni S, Colì L, Cianciolo G, Donati G, Ruggeri G, Ramazzotti E, Pohlmeier R, Lang D. Inflammatory response of a new synthetic dialyzer membrane. A randomized crossover comparison between polysulfone and helixone. Int J Artif Organs 2003; 26: 26-32.
36. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 1034-9.
37. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 1991; 337: 776-8.
38. Wiest R, Das S, Cadelina G, Garcia Tsao G, Miltsien S, Grozsman RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
39. Daurgirdas JT. Pathophysiology of dialysis hypotension: An update. Am J Kidney Dis 2001; 38: (4 suppl 4): S11-7.
40. Awad SS, Sawada S, Solded OS, Rich PB, Klein R, Alarcon WH, Wang SC, Bartlett RH. Can the clearance of tumor necrosis factor alpha and interleukin 6 be enhanced using an albumin dialysate hemodiafiltration system? ASAIO J 1999; 45: 47-9.
41. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure. JAMA 2003; 289: 217-22.
42. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 709-12.
43. Oliviero A, Mercurio G, Pilato F, Accurso A, Saturno E, Pennisi MA, Mignani V, Gaspan R, Gasbarrini A, Di Campli C, Caminiti G, Gentiloni N, Di Lazzaro V. Motor cortex excitability in severe liver failure: Effects of molecular adsorbent recycling system. Z Gastroenterol 2001; 39 (suppl 2): S47.